Daily Cosmetic Research Analysis
Analyzed 19 papers and selected 3 impactful papers.
Summary
Three high-impact studies span dermatology, reconstructive surgery, and head and neck oncology. A meta-analysis confirms ruxolitinib cream significantly improves atopic dermatitis outcomes with safety comparable to vehicle; a modified PAPF-based ICTM flap design enhances speech, swallowing, and cosmetic results after total tongue reconstruction; and a simple margin-to-depth of invasion ratio (MDR≥0.35) robustly stratifies survival in locally advanced oral cancer.
Research Themes
- Topical JAK inhibition efficacy and safety in atopic dermatitis
- Surgical design optimization to improve functional and cosmetic outcomes in tongue reconstruction
- Prognostic risk stratification using margin-to-depth ratio in oral squamous cell carcinoma
Selected Articles
1. Ruxolitinib cream improves outcomes in atopic dermatitis: An updated systematic review and meta-analysis.
Across five RCTs (n=1912), ruxolitinib cream markedly improved IGA-TS and EASI75 at weeks 4 and 8 and reduced pruritus versus vehicle, with similar rates of treatment-emergent adverse events. Benefits were consistent across ages and doses, and trial sequential analysis supported robustness.
Impact: This synthesis delivers high-level evidence that a topical JAK1/2 inhibitor is effective and well tolerated in atopic dermatitis, informing steroid-sparing strategies.
Clinical Implications: Ruxolitinib cream can be considered as a steroid-sparing option for mild-to-moderate AD to rapidly improve signs and pruritus over 4–8 weeks, with safety similar to vehicle. Head-to-head trials versus topical corticosteroids or calcineurin inhibitors are needed before guideline changes.
Key Findings
- Improved IGA-TS at 4 weeks (RR 4.56) and 8 weeks (RR 4.00) versus vehicle
- Improved EASI75 at 4 weeks (RR 3.10) and 8 weeks (RR 3.16)
- Pruritus NRS response increased (RR 2.39) and TEAE risk was comparable to vehicle (RR 0.87)
- Benefits consistent across ages and doses; trial sequential analysis confirmed robustness
Methodological Strengths
- PRISMA-guided systematic search and selection with five RCTs pooled (n=1912)
- Trial sequential analysis and subgroup analyses across age groups and doses
Limitations
- Comparators were vehicle controls; lack of head-to-head trials versus active standards
- Short treatment duration (up to 8 weeks) limits conclusions on long-term safety and durability
Future Directions: Conduct head-to-head trials versus topical corticosteroids/calcineurin inhibitors, evaluate long-term safety including infection and systemic absorption risks, and assess real-world effectiveness and steroid-sparing impact.
Atopic dermatitis (AD) is a chronic skin disease marked by pruritus and barrier disruption. Though topical corticosteroids are standard, prolonged use may cause adverse effects. This updated meta-analysis assesses the efficacy and safety of ruxolitinib cream, a topical JAK1/JAK2 inhibitor, versus vehicle in AD treatment. PubMed, Embase, and Cochrane were searched up to April 2025 for RCTs evaluating ruxolitinib versus vehicle, following Cochrane and PRISMA guidelines. Primary outcomes included Investigator's Global Assessment-Treatment Success (IGA-TS) and 75% improvement in the Eczema Area and Severity Index (EASI75) at weeks 4 and 8; secondary outcomes included ≥4-point improvement in pruritus Numeric Rating Scale (NRS) at week 8 and incidence of at least one treatment-emergent adverse event (TEAE). Five RCTs (n = 1912) were included. Ruxolitinib significantly improved IGA-TS at 4 weeks (RR 4.56; 95% CI 3.01-6.92; p < .001) and 8 weeks (RR 4.00; 95% CI 2.97-5.38; p < .001), and EASI75 at 4 weeks (RR 3.10; 95% CI 1.79-5.38; p < .001) and 8 weeks (RR 3.16; 95% CI 2.21-4.51; p < .001). Benefits were consistent across age groups and dosages. Trial sequential analysis confirmed results' robustness. Pruritus NRS improved (RR 2.39; 95% CI 1.62-3.53; p < .001). TEAE risk was similar (RR 0.87; 95% CI 0.74-1.03; p = .10), though adolescents/adults had fewer events (RR 0.83; 95% CI 0.69-1.00; p = .04); children showed no significant increase (RR 1.14; 95% CI 0.74-1.75; p = .55). Ruxolitinib cream significantly improves IGA-TS, EASI75, and pruritus, with a comparable safety profile to vehicle.
2. The Modified "ICTM" technique for total tongue reconstruction using profund artery perforator flap.
In a retrospective comparison (n=58), PAPF flaps designed via a modified ICTM method yielded better neotongue volume/contour and significantly improved speech intelligibility, swallowing, and cosmetic appearance compared with conventional designs.
Impact: Introduces a reproducible design strategy that quantifiably enhances both function and cosmesis in a challenging reconstructive setting.
Clinical Implications: Adopting the modified ICTM approach for PAPF in total tongue reconstruction may improve speech and swallowing outcomes while optimizing cosmetic appearance, informing preoperative planning and flap design.
Key Findings
- Modified ICTM PAPF achieved improved neotongue volume, contour, and sustained protuberance
- Significant gains in speech intelligibility (p=0.023) and swallowing function (p=0.008)
- Enhanced cosmetic appearance versus conventional flap design (p=0.001)
Methodological Strengths
- Comparative cohort with standardized functional and aesthetic outcome scales
- Clear statistical thresholds (p<0.05) and reporting of group-level differences
Limitations
- Retrospective, nonrandomized single-center design with potential selection bias
- Follow-up duration and blinded assessments were not specified
Future Directions: Prospective multicenter trials with longer follow-up, incorporation of 3D planning and objective volumetric metrics, and patient-reported outcome measures to validate generalizability.
OBJECTIVE: Total tongue reconstruction is one of the most complex procedures in head and neck surgery. Achieving favorable functional outcomes requires a free flap with sufficient volume and precise design. This study aimed to evaluate the clinical application of the modified "Individualized and Convenient Tongue Model" (ICTM) technique for total tongue reconstruction using profunda artery perforator flaps (PAPF). METHODS: This retrospective study included 58 participants who underwent total tongue reconstruction with PAPFs between January 2018 and December 2023. Of these, 29 underwent reconstruction using the modified ICTM technique, while 29 received the conventional flap design. Functional and aesthetic outcomes were assessed using standardized evaluation scales. Statistical analysis was performed, with a p-value <0.05 considered significant. RESULTS: PAPFs designed with the modified ICTM technique successfully reconstructed neotongues with improved volume, contour, and sustained protuberance compared to the conventional group. Participants in the modified ICTM group demonstrated significantly greater improvements in speech intelligibility (p = 0.023), swallowing function (p = 0.008), and cosmetic appearance (p = 0.001). CONCLUSIONS: For total tongue reconstruction, PAPFs designed with the modified ICTM technique offer superior closure of oropharyngeal wounds and enhanced functional and aesthetic outcomes compared to conventional flap designs.
3. Impact of margin to depth of invasion ratio on oncologic outcome in locally advanced oral cancer undergoing surgery and chemoradiotherapy.
Among 422 LAOSCC patients receiving surgery plus adjuvant CCRT, an MDR cutoff of 0.35 robustly stratified OS, CSS, and RFS, remaining independently prognostic even with adequate margins and validated via cross-validation.
Impact: Provides a simple, reproducible metric leveraging routinely reported pathology variables to refine postoperative risk stratification and follow-up planning.
Clinical Implications: Incorporating MDR (cutoff 0.35) into postoperative assessment may identify patients who require intensified surveillance or tailored adjuvant strategies despite apparently adequate margins.
Key Findings
- Optimal MDR cutoff of 0.35 predicted survival across OS, CSS, and RFS
- High MDR (≥0.35) associated with better 5-year OS (66.1% vs 47.6%), CSS (77.5% vs 57.4%), and RFS (71.5% vs 53.8%)
- Low MDR remained an independent adverse factor in multivariate analysis; prognostic value persisted even with ≥5 mm margins
- Threshold robustness confirmed by repeated k-fold cross-validation
Methodological Strengths
- Large single-institution cohort with multivariate Cox regression
- Data-driven cutoff using X-tile and internal validation with repeated k-fold cross-validation
Limitations
- Retrospective single-center design with potential confounding and selection biases
- Lack of external validation; temporal changes in surgical and adjuvant practices may influence outcomes
Future Directions: Prospective external validation across centers, integration of MDR into prognostic nomograms, and exploration of preoperative imaging surrogates to estimate MDR.
OBJECTIVES: This study aimed to evaluate the prognostic value of the margin-to-depth of invasion ratio (MDR) in patients with locally advanced oral squamous cell carcinoma (LAOSCC) who underwent curative surgery followed by adjuvant concurrent chemoradiotherapy (CCRT). METHODS: We analyzed 422 consecutive LAOSCC patients treated at a single institute between 2007 and 2017. The MDR was defined as the ratio of the closest surgical margin (mm) to tumor depth of invasion (DOI, mm). Survival outcomes, including overall survival (OS), cancer-specific survival (CSS) and relapse-free survival (RFS) were assessed. The optimal MDR cutoff was determined by X-tile analysis and validated using repeated k-fold cross-validation. RESULTS: The optimal MDR cutoff for predicting survival was 0.35. Patients with MDR ≥ 0.35 (high MDR, n = 205) demonstrated significantly better 5-year OS (66.1% vs. 47.6%, p < 0.001), CSS (77.5% vs. 57.4%, p < 0.001), and RFS (71.5% vs. 53.8%, p = 0.001) compared with those with MDR < 0.35 (low MDR, n = 217). In multivariate analysis, low MDR remained an independent adverse prognostic factor for OS (HR = 1.61, p = 0.005), CSS (HR = 2.05, p = 0.001) and RFS (HR = 1.50, p = 0.033). Among patients with adequate margins (≥5 mm), MDR retained significant prognostic value (OS, p = 0.008; CSS, p = 0.001; RFS, p = 0.015). Cross-validation confirmed the robustness of the MDR threshold value of 0.35 across all survival endpoints. CONCLUSION: MDR is an independent prognostic marker in LAOSCC treated with surgery and adjuvant CCRT. A cutoff of 0.35 effectively stratifies survival risk, even among patients with adequate surgical margins. Incorporating MDR into postoperative assessment could refine risk stratification and guide individualized follow-up and adjuvant treatment planning.